Clinical-development physician must resolve whether to drop a secondary

Situation

FDA Response and Labeling work in a company with a CMC site change mid-review now turns on to drop a secondary because a boxed-warning proposal from the review division put advisory-committee question list that exposes a weak secondary endpoint in play. Clinical-development physician should say what advisory-committee question list that exposes a weak secondary endpoint proves.

Decision

Clinical-development physician in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a boxed-warning proposal from the review division.

Hypotheses to test

• Advisory-committee question list that exposes a weak secondary endpoint reads as Proceed under protocol once a boxed-warning proposal from the review division is lined up to the same Pharma & Life Sciences population.
• Advisory-committee question list that exposes a weak secondary endpoint is closer to Pause the pathway after a boxed-warning proposal from the review division; Proceed under protocol would over-claim this FDA Response and Labeling extract.
• Escalate safety review is still live in advisory-committee question list that exposes a weak secondary endpoint for clinical-development physician in a company with a CMC site change mid-review.
• Advisory-committee question list that exposes a weak secondary endpoint is missing the fact clinical-development physician needs after a boxed-warning proposal from the review division; stop this Pharma & Life Sciences close.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary.
• Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• For this Pharma & Life Sciences FDA Response and Labeling file, read advisory-committee question list that exposes a weak secondary endpoint against a boxed-warning proposal from the review division and write the one fact that would move to drop a secondary for clinical-development physician.

Recommendation